Publications

After a brief introduction on selective laser melting (SLM) and “ex situ” manufacture of metal matrix composites (MMCs), this paper reviews the capacities and benefits of SLM to activate and control various “in situ” reactions during fabrication of 3D parts. It introduces several systems (such as Al/Fe 2 O 3 , AlSi10Mg/SiC, Al/ZnO, Ti/C, Ti/SiC, Ti/Si 3 N 4 , Ti/Mo 2 C, Fe/SiC, etc.) used to manufacture Al‐based, Ti‐based, and steel‐based “in situ” MMCs. Then, it illustrates the novel microstructural characteristics of these SLM‐made “in situ” MMCs for different cases, as they may appear from nano‐particles to nano‐whiskers and dendritic reinforcements homogeneously distributed in a metal matrix. It also focuses on SLM associated “in situ” mechanisms, explaining how an “in situ” reaction propagates based on “decomposition, diffusion, and reformation” and how the growth mechanisms turn into different morphologies such as rounded particles, whiskers, or polygonal block shapes. The influence of various SLM parameters (such as energy density, laser power/speed, powder layer thickness, and the size of initial powder particles) and the SLM “in situ” challenges are also discussed.

Abstract For Abstract see ChemInform Abstract in Full Text.

Several drug-resistant herpes simplex virus type 1 (HSV-1) strains were obtained under the selective pressure of various antiherpetic drugs used alone or in combination. Their susceptibility to a wide range of antiviral compounds was determined. Strains selected under the pressure of brivudin (BVDU) or 1-β-D-arabinofuranosyl-( E)-5-(2-bromovinyl)uracil (BVaraU) alone were composed of two virus populations: (1) virus resistant to BVDU and BVaraU but not to acyclovir (ACV) or ganciclovir (GCV), which is suggestive of an alteration in the thymidylate kinase activity associated with the viral thymidine kinase (TK) (responsible for the phosphorylation of BVDU-monophosphate to BVDU-diphosphate); and (2) virus resistant to BVDU, BVaraU, ACV and GCV, which is indicative of an alteration in the viral TK activity that converts BVDU, BVaraU and other nucleoside analogues such as ACV and GCV to their monophosphate derivatives. Strains resistant to TK-dependent drugs (i.e. ACV, GCV, BVDU and BVaraU) as well as double-mutant strains with decreased sensitivity to both TK-dependent compounds and the pyrophosphate analogues foscarnet (PFA) and phosphonoacetic acid (PAA) (suggestive of mutations at the level of the DNA polymerase) were recovered under the selective pressure of ACV alone or in combination with BVDU or BVaraU. Combinations of BVDU or BVaraU with PFA or PAA led to strains resistant only to BVDU and BVaraU or double-mutant strains resistant to BVDU, BVaraU and the pyrophosphate analogues, but not to strains resistant to other TK-dependent drugs. Interestingly, strains resistant to ACV, BVDU, GCV and/or the pyrophosphate analogues PFA and PAA remained sensitive to the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA).

9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) is a broad-spectrum antiviral agent with potent activity against DNA viruses and retroviruses. We now demonstrate that PMEDAP is highly efficacious when given orally to mice infected with either Moloney murine sarcoma virus (MSV), Friend leukemia virus (FLV), or murine cytomegalovirus (MCMV). PMEDAP markedly delayed MSV-induced tumor initiation when administered orally at 50, 100, or 250 mg/kg/day during 5 subsequent days. At the highest dose (250 mg/kg/day), PMEDAP completely prevented tumor formation in the MSV-infected animals. PMEDAP also caused 84-96% inhibition of FLV-induced splenomegaly when given orally to FLV-infected mice at 50-250 mg/kg/day. These PMEDAP treatment regimens were also markedly effective in increasing the survival rate of MCMV-infected mice. Intraperitoneal PMEDAP achieved a comparable antiviral activity at 2- to 5-fold lower doses than oral PMEDAP. However, the therapeutic index (ratio of the toxic dose to the antivirally effective dose) of oral PMEDAP was substantially higher than that of intraperitoneal PMEDAP. Oral PMEDAP at doses of 100, 250, or 500 mg/kg resulted in plasma PMEDAP levels of 0.5-2.5 micrograms/ml, which were sustained for 3 or 6 hours after administration and may account for the high antiviral efficacy achieved.

Abstract A series of new o ne t wo subtituted c arbonucleoside analogues (OTC) of purine was synthesized and evaluated against cytomegalovims and varicella-zoster virus in human embryonic lung (HEL) cells.

A series of alkyl-aryl, -phenoxy, and -thiophenoxy bicyclic furo pyrimidine nucleosides have been successfully synthesised by Pd-coupling of 5-iodo-2'-deoxyuridine (IDU) with terminal alkynes, followed by in situ copper-cyclisation. Synthesised compounds (4a-i) showed an anti-VZV activity at low microM concentration, comparable to that of current treatment acyclovir.

Thales Electron Devices has been pursuing since 2003 frequency standards activities. In the framework of these activities, Thales established a consortium for the development of a space Cs atomic clock for Galileo. This consortium is composed by two of the best scientific laboratories in the European Time-Frequency community : the Observatoire de Neuchâtel (ON) and the SYRTE Observatoire de Paris, and by two space industrials : Oerlikon Space AG (OSAG) and Thales Electron Devices. The name of the project is OSCC for Optically pumped Space Cs Clock. The first phase (phase A) of this development started in June 2006 under an ESA contract. The purpose of this phase A is a feasibility study of Cs clock technology for Galileo with the manufacturing and the test of a new compact optically pumped Cs clock breadboard. This technology is well known in laboratories but it has never been industrialized, even for ground applications. This study starts with a strong background at SYRTE and ON, but also with new industrial developments realized at Thales during the last years. Frequency stability in order of 1 to 3×10 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">-12</sup> .τ <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">-½</sup> has been already demonstrated in lab with different configurations. This document will first synthesize the last results obtained by each Partner, followed by the results of the existing hardware analysis performed in the first step of the project. This analysis allowed Partners to share their know-how and to identify the limits of each existing breadboards with respect to the objectives of the project.